Using a new cannabinoid to target inflammation in HIV patients
Targeting Inflammasome with stable endocannabinoid ligand AMG315. CRISPR/Cas9 and nanotechnology study in the context of HIV and cannabinoid
['FUNDING_R01'] · FLORIDA INTERNATIONAL UNIVERSITY · NIH-10847335
This study is looking at a new treatment called AMG315 that might help reduce inflammation and HIV infection in the brain for people living with HIV, using advanced technology to target specific genes and improve brain health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FLORIDA INTERNATIONAL UNIVERSITY (nih funded) |
| Locations | 1 site (MIAMI, UNITED STATES) |
| Trial ID | NIH-10847335 on ClinicalTrials.gov |
What this research studies
This research investigates the potential of a stable endocannabinoid ligand, AMG315, to reduce inflammation and HIV infection in the brain. By utilizing CRISPR/Cas9 gene-editing technology, the study aims to eliminate the HIV-1 Tat gene from central nervous system cells, which is linked to neuroinflammation and cognitive impairments in HIV patients. The approach combines advanced nanotechnology with cannabinoid therapy to address both the viral infection and its inflammatory consequences. Patients may be monitored for changes in neurocognitive function and overall health as part of the research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who experience neurocognitive impairments and inflammation.
Not a fit: Patients who are not living with HIV or those who do not experience related neurocognitive issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for HIV patients, potentially reducing inflammation and cognitive decline associated with the disease.
How similar studies have performed: While the use of CRISPR technology in HIV treatment is emerging, the specific combination of AMG315 and CRISPR/Cas9 for targeting neuroinflammation in HIV is relatively novel and has not been extensively tested.
Where this research is happening
MIAMI, UNITED STATES
- FLORIDA INTERNATIONAL UNIVERSITY — MIAMI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAKSHMANA, MADEPALLI KRISHNAPPA — FLORIDA INTERNATIONAL UNIVERSITY
- Study coordinator: LAKSHMANA, MADEPALLI KRISHNAPPA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.